U.K. snubs Avastin; Pfizer must pay opposing lawyers $180M; Valeant closes Russian deal;

@FiercePharma: Genzyme's $176K Kynamro price undercuts its $250K-plus rival. But rivalry in orphan drugs isn't the usual. Article | Follow @FiercePharma

@EricPFierce: Medicare refiguring how it will pay for dialysis drugs. It is part of the new payer world. More | Follow @EricPFierce

> The U.K. cost watchdog NICE has recommended against use of Roche's ($RHHBY) cancer drug Avastin for treating advanced ovarian cancer that has returned after chemotherapy. Release

> A consent decree on Boehringer Ingelheim's Ben Venue Laboratories' Bedford, OH, plant has been approved, putting strict limits on production there. Release

> New rates from Medicare for dialysis drugs will be put in place next year. Story

> Bristol-Myers Squibb ($BMY) reportedly wants to cash in on high demand for consumer lines by selling some of its product lines in Mexico and Brazil. Story  

> Valeant Pharmaceuticals ($VRX) has completed its acquisition of Natur Produkt for about $163 million. Release

> Actavis has lost a patent case over its generic version of Pfizer's ($PFE) Rapamune used in organ transplants. Release

> An Arkansas judge has ordered Johnson & Johnson ($J&J) to pay $181 million in legal fees to lawyers who beat it in a case over marketing of its antipsychotic drug Risperdal. Story

> China's Luqa Pharmaceuticals says it is launching in China Strataderm Gel for treating scars. Release

Medical Device News

 @FierceMedDev: New special report: Top diagnostics VC investments of 2012. More | Follow @FierceMedDev

 @MarkHFierce: Philips Healthcare had a solid Q4--the overall company, less so. More | Follow @MarkHFierce

 @DamianFierce: Add Smith & Nephew to the list of companies cutting jobs and blaming the 2.3% medical device tax. Report | Follow @DamianFierce

> GE pursues 'corrective action' for more parts used in two infant warmers. Article

> Ivantis hauls in $27M for tiny eye stent. Story

> MITA: CMS should weigh Dx endpoints for beta amyloid PET imaging coverage. Item

Biotech News

 @FierceBiotech: Juventas snaps up business development veteran, more in this week's roundup of hirings and firings in biotech, pharma. More | Follow @FierceBiotech

@JohnCFierce: Odana is one of Merck's top PhIII drugs, and like suvorexant may not sell well against generics. Where's the breakthrough strategy? More | Follow @JohnCFierce

@RyanMFierce: Gilead hungers for more cancer drug deals. But Ariad? Story | Follow @RyanMFierce

> GlaxoSmithKline shoots for combo attack against melanoma in surgery patients. News

> Bayer spotlights positive PhIII data for fat-busting drug. Article

> Merck R&D calls for a time-out on osteo blockbuster hopeful. Report

And Finally... Pfizer ($PFE) finds itself defending a lawsuit that says its popular antidepressant doesn't work. Story